Fig. 4. (a) In vitro release profile of developed formulations (n = 3); (b) ex vivo drug permeation efficiency of plain insulin and C4T4I4 (n = 3); (c) blood glucose level (% of increased initial level) in diabetic rabbits after ocular administration of control, optimized C4T4I4, plain insulin solution, and subcutaneous insulin injection (n = 3).
